Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD

PHASE3CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

December 31, 2015

Conditions
Diabetes, Type IDiabetes, Type IIAnginaCoronary Artery Disease
Interventions
DRUG

Ranolazine

Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.

DRUG

Placebo

Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT01754259 - Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD | Biotech Hunter | Biotech Hunter